Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | APAF1 | O14727 | 4/20 | 0.35 |
| ▸ | LMNA | P02545 | 3/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.34 |
| ▸ | PTPRA | P18433 | 1/20 | 0.33 |
| ▸ | KMO | O15229 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20703191 | 1.00 | ALDH1A1 (0.39) | ALDH1A1APAF1LMNAPOLBOR51E2 | |
| SCHEMBL23138142 | 0.82 | CYP1A2 (0.39) | ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL23118150 | 0.76 | ALDH1A1 (0.37) | ALDH1A1OR51E2PTPRAKMO | |
| SCHEMBL23118151 | 0.76 | ALDH1A1 (0.37) | ALDH1A1OR51E2PTPRAKMO | |
| SCHEMBL10308972 | 0.74 | LMNA (0.43) | ALDH1A1LMNAPOLBHTTMAPT | |
| SCHEMBL21233331 | 0.66 | — | — | |
| SCHEMBL20702684 | 0.66 | EGLN3 (0.52) | ALDH1A1 | |
| SCHEMBL20702682 | 0.66 | EGLN3 (0.52) | ALDH1A1 | |
| SCHEMBL14908425 | 0.66 | KDM4E (0.41) | ALDH1A1APAF1LMNAPOLBMAPT | |
| SCHEMBL20705348 | 0.66 | KMO (0.42) | ALDH1A1APAF1LMNAPOLBOR51E2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111356680-B | Selective inhibitors of NLRP3 inflammasome | 诺瑟拉有限公司 | 2023-11-28 | — | — | CN | disclosed |
| EP-3661921-B1 | SELECTIVE INHIBITORS OF NLRP3 INFLAMMASOME | NODTHERA LTD (GB) | 2023-10-18 | — | — | EP | disclosed |
| US-20210087147-A1 | SELECTIVE INHIBITORS OF NLRP3 INFLAMMASOME | NodThera Limited (GB) | 2021-03-25 | — | — | US | disclosed |
| CN-111356680-A | Selective inhibitors of NLRP3inflammasome | 诺瑟拉有限公司 | 2020-06-30 | — | — | CN | disclosed |
| EP-3661921-A1 | SELECTIVE INHIBITORS OF NLRP3 INFLAMMASOME | Nodthera Limited (GB) | 2020-06-10 | — | — | EP | disclosed |
| WO-2019025467-A1 | SELECTIVE INHIBITORS OF NLRP3 INFLAMMASOME | NodThera Limited (GB) | 2019-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210087147-A1 | SELECTIVE INHIBITORS OF NLRP3 INFLAMMASOME | NLRP3, NOD1, NLRP1 | ALDH1A1 961/4885APAF1 22/4885LMNA 1234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.